Navigation Links
HeartWare Schedules Fourth Quarter Conference Call and Webcast
Date:2/19/2013

FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2012, at 8:30 a.m. U.S. Eastern Standard Time on Wednesday, February 27, 2013. The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the fourth quarter and business outlook.  The call may be accessed by dialing 1-888-846-5003 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9856.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Completes Acquisition Of World Heart Corporation
9. HeartWare Reports Second Quarter 2012 Results
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology ... for the ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards ... Executive Forum and Awards Gala on March 15, 2016 at the Westin Peachtree ...
(Date:2/12/2016)... ... ... AssureVest Insurance Group, a locally owned insurance firm with offices serving Washington NC ... to purchase computers and software for Mrs. Harrison’s 2nd and 3rd grade special needs ... area and has more than 60 2nd and 3rd graders with learning disabilities. A ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement ... announced a partnership with San Ramon Regional Medical Center. Under the collaboration, the first ... a way to accommodate a more certain time frame for donor families for the ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... choices that promote eye health. These articles generally list between five and 15 ... advocate Sharon Kleyne endorses every one of these lists and believes that nutritious ...
(Date:2/12/2016)... ... February 12, 2016 , ... Healthcare careers in the medical laboratory, nursing, and ... the website of healthcare staffing leader Aureus Medical Group during the month of January. ... travel therapy positions and in travel and direct hire opportunities in other allied ...
Breaking Medicine News(10 mins):